Are 200 units of onabotulinumtoxin A sufficient for the suppression of neurogenic detrusor overactivity in individuals with established 300-unit botulinum toxin treatment? A retrospective cohort study

Krebs, Jörg; Pannek, Jürgen; Rademacher, Franziska; Wöllner, Jens

doi:10.1007/s00345-020-03211-1

Cited by 5 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients treated with 300 U of Botox had similar therapeutic efficacy after 200 U of Botox treatment. The number of episodes of urinary incontinence and daily pad use were similar between the two dosage phases [ 51 ]. However, quality-of-life measures were significantly improved, and an improvement in end-filling pressure and bladder compliance was also reported [ 52 ].…”

Section: Clinical Application Of Botox On Ndo: Efficacy Adherence Adv...mentioning

confidence: 99%

Clinical Application of Botulinum Neurotoxin in Lower-Urinary-Tract Diseases and Dysfunctions: Where Are We Now and What More Can We Do?

Kuo

2022

Toxins

View full text Add to dashboard Cite

Botulinum toxin A (Botox) had been considered a promising drug that has an effect on functional disorders of the lower urinary tract. Because Botox exhibits anti-inflammatory and antispasmodic effects, Botox injection into the bladder can decrease detrusor contractility, reduce bladder hypersensitivity, and eliminate painful sensations. Injecting Botox into the bladder outlet can relax the hyperactivity of the bladder neck, and of the urethral smooth and striated muscles. Based on these therapeutic effects, Botox has been widely applied to treat lower-urinary-tract dysfunctions (LUTDs) such as overactive bladder and neurogenic detrusor overactivity. However, this treatment has not been licensed for use in other LUTDs such as interstitial cystitis, voiding dysfunction due to benign prostatic hyperplasia in men, and dysfunctional voiding in women. Botox has also not been approved for the treatment of children with overactive bladder and dysfunctional voiding; in patients with spinal cord injuries with detrusor sphincter dyssynergia and autonomic dysreflexia; or for poorly relaxed external sphincter in non-neurogenic patients. This article reviews the current knowledge regarding Botox treatment for LUTDs and discusses the potential clinical applications of Botox, as well as work that can be conducted in the future.

show abstract

Section: Clinical Application Of Botox On Ndo: Efficacy Adherence Adv...mentioning

confidence: 99%